METiS TechBio, the World's First Publicly Listed AI-Powered Drug Delivery Company, Debuts on the Hong Kong Stock Exchange, "The SpaceX of Pharmaceuticals" Usher…
METiS TechBio (7666.HK), an AI-powered drug delivery company, became the world's first publicly listed AI nanodelivery biopharmaceutical firm on the Hong Kong Stock Exchange, raising over HKD 2.1 billion with a record-breaking 6,900x oversubscription. The company aims to revolutionize biomedicine by using AI-driven 'nano-rockets' to reprogram cells, with backing from global investors including BlackRock and state-level funds.
METiS TechBio (7666.HK), a Hong Kong-listed tech-bio company specializing in AI-powered nanodelivery, marked a global first by becoming the world’s first publicly traded AI-driven drug delivery firm. The company’s IPO on the Hong Kong Stock Exchange (HKEX) in May 2026 raised over HKD 2.1 billion, the largest healthcare IPO in the region this year, with an unprecedented 6,900x oversubscription for its public offering and 82x for international placements. The IPO was led by Jefferies, Deutsche Bank Securities Asia, and CITIC Securities (Hong Kong), securing USD 148 million from 18 cornerstone investors, including BlackRock, UBS Asset Management, and state-level funds like Guofengtou Innovation Investment Fund. Investors spanning global asset managers, AI-focused funds, and Chinese public fund managers demonstrated strong confidence in AI nanodelivery as a strategic technology for future biopharmaceutical advancements. Founded six years prior, METiS TechBio is described as the 'SpaceX of pharmaceuticals' for its ambition to develop AI-powered 'nano-rockets' capable of navigating the human body’s 30 trillion cells to reprogram diseased or aging cells. CEO Dr. Chris Lai emphasized the company’s mission to shift biomedicine from reactive treatment to proactive cellular reprogramming, leveraging the IPO to accelerate research and development. The company’s technology has gained recognition as a national priority in China, with participation from specialized healthcare funds like Deerfield and Lake Bleu Capital, alongside technology investors such as Walden International and Hillhouse Capital. METiS TechBio’s listing underscores the growing intersection of AI and biopharmaceuticals, positioning it as a key player in the future of precision medicine. Key figures involved include Co-Founders Dr. Chris Lai (CEO), Wenshou Wang (COO), and Hongming Chen (CRDO), alongside independent directors and executives like Jin Li and Peter Edward Lobie. The IPO’s success reflects both investor enthusiasm and the company’s rapid growth as the fastest unicorn in China’s AI pharmaceutical sector to reach this milestone.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.